drugset / Trial / NCT00167661

Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation

NCT00167661

Phase 1/2 Terminated 33 enrolled University of Wisconsin, Madison
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Campath-1H induction and the associated lymphocyte depletion will permit long-term rejection-free renal allograft survival in the absence of ongoing corticosteroid administration.

Timeline

Start
2004-06
Primary completion
2011-12
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody 20 mg/m2 Intravenous